Table 3 Validity of serum AAR, APRI, FIB-4 and FI in 157 HCV infected patients

< 1

42.8

67.6

88.4

16.9

92/44

12/9

0.468[0.377-0.559]

> 1

67.6

42.8

16.9

88.4

44/92

9/12

0.610[0.483-0.738]

Cutoff value

Spe%

Sen%

PPV%

NPV%

F0-F1 (n = 68)

F2-F4 (n = 89)

AUC [95% CI]

< 0.5

97.7

19.1

86.6

61.2

13/55

2/87

0.715[0.635-0.795]

> 1.5

67.6

34.8

58.4

44.2

22/46

31/58

0.876[0.782-0.971]

Cutoff value

Spe%

Sen%

PPV%

NPV%

F0-F2 (n = 102)

F3-F4 (n = 55 )

AUC [95% CI]

< 1.45

85.4

51

86.6

48.4

52/50

8/47

0.732 [0.655-0.809]

> 3.25

82.3

59.2

64

79.2

18/84

33/22

0.545[0.456-0.635]

Cutoff value

Spe%

Sen%

PPV%

NPV%

F0-F1 (n = 68)

F2-F4 (n = 89)

AUC [95% CI]

< 2.1

58.4

100

64.7

100

68/0

37/52

0.939[0.903-0.974]

Cutoff value

Spe%

Sen%

PPV%

NPV%

F0-F3 (n = 136)

F4 (n = 21)

AUC [95% CI]

> 3.3

100

38.1

100

91.2

0/136

8/13

0.990[0.979-1.001]